Skip to main content
HR 2534 118th Congress House Health

PROTECT 340B Act of 2023

Introduced: October 26, 2023 See on congress.gov
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 17, 2024
Referred to the Subcommittee on Health.
Apr 14, 2023
Referred to the Subcommittee on Health.
Apr 6, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 6, 2023
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Preserving Rules Ordered for The Entities Covered Through 340B Act of 2023 or the PROTECT 340B Act of 2023

This bill prohibits pharmacy benefit managers (PBMs) and health insurance plans from discriminating against health providers participating in the 340B drug pricing program, including pharmacies contracted with such providers to dispense 340B drugs. The 340B program allows certain providers to receive covered outpatient drugs at reduced prices from manufacturers.

Specifically, PBMs and insurance plans may not

  • reimburse 340B participants at a lower rate than other entities not participating in the program;
  • impose differing terms (such as fees, charge-backs, or audits) on 340B participants;
  • interfere with an individual's choice to receive drugs from a 340B participant;
  • require 340B participants to identify which drugs fall within the program; or
  • refuse to contract with a 340B participant on the basis that they utilize the program.

Further, insurance plans may not deny coverage of drug because it is a 340B drug.

Violations of this bill are subject to a civil penalty of not more than $5,000 per violation per day.

These prohibitions also apply to prescription drug (Part D) sponsors under Medicare.

The bill also provides for a process to prevent duplicate 340B drug discounts to states under Medicaid.

What's happening now December 17, 2024

Referred to the Subcommittee on Health.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 36
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2534: PROTECT 340B Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-HR-2534/
MLA
"H.R. 2534: PROTECT 340B Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-2534/.
Bluebook (legal)
H.R. 2534, 118th Cong. (2026), https://openamerica.io/bill/118-HR-2534/.
Markdown link
[H.R. 2534: PROTECT 340B Act of 2023](https://openamerica.io/bill/118-HR-2534/)
Report a problem